抗癌薬TS-1®の全身投与が原因と考えられた角膜上皮障害

Corneal epithelial lesion presumably due to anticancer drug TS-l®

要約　目的：抗癌薬TS-1^®が原因と考えられる角膜上皮障害の報告。対象と方法：テガフール，ギメラシル，オテラシルカリウムを含む抗癌薬TS-1^®で加療中に角膜上皮障害が生じた7例14眼を解析した。結果：男性5例，女性2例であり，年齢は71.3±8.0歳であった。原疾患の内訳は胃癌4例，乳癌，大腸癌，胆管癌各1例であった。TS-1^®の投与開始から眼科受診までの期間は平均4.0か月で，それまでの総投与量は平均7.9gであった。全例が両眼性で，充血を伴わない角膜上皮障害があった。TS-1^®投与を中止した5例10眼では所見が改善したが，投与を継続した2例4眼では角膜上皮障害が持続した。結論：抗癌薬TS-1^®の全身投与で角膜上皮障害が生じる可能性があり，注意が必要である。

Abstract.　Purpose：To report corneal epithelial lesion in patients treated by anticancer drug TS-l^® that contains tegafur, gimeracil and oteracil potassium. Cases and Method：This retrospective study was made on 14 eyes of 7 patients who developed corneal lesion during systemic treatment with TS-l^®. Results：The present series comprised 5 males and 2 females. Their age averaged 71.3±8.0 years. The cancer was located in the stomach in 4 cases, breast, colon and bile duct in one case each. They had been receiving TS-1^® totalling 7.9g for an average of 4.0 months before seeking advice for eye problems. All were bilaterally affected by corneal epithelial lesion without hyperemia. Spontaneous cure set in 10 eyes of 5 cases after discontinuation of TS-1^®. The keratopathy persisted in the other 4 eyes of 2 cases who continued the treatment. Conclusion：Systemic treatment with TS-1^® may induce corneal epithelial disorder as a side effect.